Pharmafile Logo
Pharmafocus logo
Advanced Search

Oncology

Showing 15 posts of 310 posts found.

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025
Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …

News
europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025
Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …

News

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development

July 29, 2025
Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer

ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …

News

Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth

July 16, 2025
Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience

Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …

Appointment
money_pills_2

VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium

July 14, 2025
Medical Communications, Research and Development Nuclidium, Oncology, VIVES Funds, VIVES Partners, radiopharmaceuticals, radiotheranostics

VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing …

News

BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design

July 11, 2025
Research and Development BioLabs, BioMed X, Cancer, Oncology, Servier, XSeed Labs, antibody therapy, oncology

BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, located at the Spartners incubator …

News

Eppendorf Award for Young European Investigators 2025 awarded to neuroscientist Varun Venkataramani

July 10, 2025
Medical Communications, Medical/ Scientific Writing, Research and Development Neurology, Oncology

Varun Venkataramani, of Heidelberg University Hospital, Germany, has been awarded the 2025 Eppendorf Award for Young European Investigators for his …

News
brain_scan_small

Duke Street Bio receives FDA fast track designation for brain metastases treatment

July 8, 2025
Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation

Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …

News
Toast Burning

Five facts about UV exposure and sun safety

July 7, 2025
Medical Communications Dermatology, Five Facts, Oncology, Skin, melanoma, skincare

1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s a sunny spell earlier in …

Feature

FDA grants accelerated approval for advanced non-small cell lung cancer treatment

July 4, 2025
Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …

News

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

July 4, 2025
Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …

News

Biocon Biologics gains EU approval for bone health therapies

July 4, 2025
Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …

News

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

June 24, 2025
Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …

News
money-2180330_960_720

Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology

June 20, 2025
Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer

Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …

News
AstraZeneca_drug_discovery

Bristol Myers Squibb to present positive new data on lymphoma treatment

June 18, 2025
Medical Communications, Research and Development Bristol Myers Squibbs, CAR T-cell therapy, International Conference on Malignant Lymphoma, Oncology, relapsed or refractory marginal zone lymphoma

Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) …

News
The Gateway to Local Adoption Series

Latest content

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer

May 22, 2026

BioDuro and CTI Biotechnology in preclinical drug development partnership

May 21, 2026

Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

May 21, 2026

NICE recommends sotatercept for pulmonary arterial hypertension

May 20, 2026

Vetter begins construction of new injectable medicines facility

May 20, 2026